Crescent Biopharma (CBIO) Change in Cash (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Change in Cash of -$17.6 million for Q2 2026, down 113.48% year-over-year from $130.3 million in Q2 2025, and up 26.88% quarter-over-quarter from -$24.0 million in Q1 2026.
Crescent Biopharma (CBIO) Change in Cash (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Change in Cash for 14 consecutive years, with -$17.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Cash fell 113.48% year-over-year to -$17.6 million; the TTM figure through Jun 2026 stood at $18.9 million (down 87.59% YoY), while the FY2025 annual figure was $178.5 million, up 674.57% from the prior year.
- Change in Cash rose to -$17.6 million in Q2 2026 per CBIO's latest filing, from -$24.0 million in the prior quarter.
- Across five years, Change in Cash topped out at $130.3 million in Q2 2025 and bottomed at -$24.0 million in Q1 2026.
- Historically, Change in Cash has averaged $6.1 million across 5 years, with a median of -$8.6 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Cash sank 201.0% — and 2025, when it soared 1565.05%.
- Crescent Biopharma's Change in Cash stood at -$3.8 million in 2022, then tumbled by 102.84% to -$7.6 million in 2023, then soared by 556.56% to $34.8 million in 2024, then jumped by 129.9% to $79.9 million in 2025, then plunged by 121.98% to -$17.6 million in 2026.
- Business Quant data shows CBIO's Change in Cash at -$17.6 million in Q2 2026, -$24.0 million in Q1 2026, and $79.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | -17.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.57 Mn |
| Mar 31, 2026 | -24.03 Mn |
| Dec 31, 2025 | 79.93 Mn |
| Sep 30, 2025 | -19.38 Mn |
| Jun 30, 2025 | 130.32 Mn |
| Mar 31, 2025 | -12.34 Mn |
| Dec 31, 2024 | 34.77 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Mar 31, 2024 | -10.51 Mn |
| Dec 31, 2023 | -7.61 Mn |
| Sep 30, 2023 | -8.63 Mn |
| Jun 30, 2023 | -6.97 Mn |
| Mar 31, 2023 | 17.13 Mn |
| Dec 31, 2022 | -3.75 Mn |
| Sep 30, 2022 | -8.62 Mn |
| Jun 30, 2022 | -16.27 Mn |
| Mar 31, 2022 | -13.74 Mn |
| Dec 31, 2021 | -11.67 Mn |
| Sep 30, 2021 | -16.93 Mn |
| Jun 30, 2021 | -13.62 Mn |